Amicus Therapeutics, Inc. Announces Positive Pompe Program Updates

CRANBURY, N.J., and PERTH, Australia, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced additional positive preliminary results from an ongoing Phase 2 open-label drug-drug interaction study (Study 010) to evaluate the safety and plasma pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme® and Lumizyme®). These Phase 2 results were presented in a poster1 at the 17th International World Muscle Society Congress in Perth, Australia. The Company also announced initial findings from ex vivo studies to characterize the immunogenicity of Myozyme and Lumizyme with and without AT2220.